Ultragenyx
RARE
Insider trades and stock quote 2024-2026
All insider trades at Ultragenyx
| Date |
Type |
Insider |
Position |
Ø-Price |
Volume |
|
8/3/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$24.9 |
$117,024 |
|
8/3/2026
|
Sell |
Parschauer, Karah Herdman |
EVP and Chief Legal Officer |
$24.9 |
$47,348 |
|
7/1/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$33.1 |
$155,645 |
|
6/15/2026
|
Sell |
Parschauer, Karah Herdman |
EVP and Chief Legal Officer |
$24.6 |
$46,753 |
|
6/15/2026
|
Sell |
Sanders, Corazon (Corsee) D. |
Director |
$25.0 |
$50,100 |
|
6/1/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$23.8 |
$110,602 |
|
5/18/2026
|
Sell |
Suliman, Shehnaaz |
Director |
$25.1 |
$144,189 |
|
5/5/2026
|
Sell |
Crombez, Eric |
EVP and Chief Medical Officer |
$25.0 |
$8,586 |
|
5/1/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$24.9 |
$116,607 |
|
4/1/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$21.0 |
$98,203 |
|
3/10/2026
|
Sell |
Parschauer, Karah Herdman |
EVP and Chief Legal Officer |
$22.7 |
$79,526 |
|
3/6/2026
|
Sell |
Parschauer, Karah Herdman |
EVP and Chief Legal Officer |
$21.4 |
$128,785 |
|
3/3/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$22.4 |
$36,624 |
|
3/2/2026
|
Sell |
Crombez, Eric |
EVP and Chief Medical Officer |
$22.8 |
$160,261 |
|
3/2/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$22.7 |
$190,914 |
|
3/2/2026
|
Sell |
Huizenga, Theodore Alan |
SVP, Chief Accounting Officer |
$22.8 |
$37,210 |
|
3/2/2026
|
Sell |
Parschauer, Karah Herdman |
EVP and Chief Legal Officer |
$22.8 |
$185,478 |
|
3/2/2026
|
Sell |
Kakkis, Emil D. |
President & CEO |
$22.8 |
$1,240,411 |
|
3/2/2026
|
Sell |
Harris, Erik |
EVP & Chief Commercial Officer |
$22.8 |
$240,289 |
|
3/2/2026
|
Sell |
Pinion, John Richard |
Officer |
$22.8 |
$228,661 |
|
2/2/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$23.6 |
$72,117 |
|
1/2/2026
|
Sell |
Horn, Howard |
Chief Financial Officer |
$22.8 |
$71,946 |
|
12/29/2025
|
Sell |
Huizenga, Theodore Alan |
SVP, Chief Accounting Officer |
$34.4 |
$2,922 |
|
12/10/2025
|
Sell |
Horn, Howard |
Chief Financial Officer |
$36.4 |
$112,087 |
|
10/13/2025
|
Sell |
Horn, Howard |
Chief Financial Officer |
$31.5 |
$250,252 |
|
9/18/2025
|
Sell |
Huizenga, Theodore Alan |
SVP, Chief Accounting Officer |
$29.2 |
$1,867 |
|
9/12/2025
|
Sell |
Parschauer, Karah Herdman |
EVP and Chief Legal Officer |
$31.2 |
$76,367 |
|
9/5/2025
|
Sell |
Huizenga, Theodore Alan |
SVP, Chief Accounting Officer |
$31.4 |
$2,637 |
|
6/20/2025
|
Sell |
Sanders, Corazon (Corsee) D. |
Director |
$37.4 |
$89,923 |
|
5/5/2025
|
Sell |
Crombez, Eric |
EVP and Chief Medical Officer |
$39.2 |
$20,405 |
|
4/21/2025
|
Sell |
Crombez, Eric |
EVP and Chief Medical Officer |
$35.1 |
$8,497 |
|
3/6/2025
|
Sell |
Horn, Howard |
Chief Financial Officer |
$40.4 |
$72,114 |
|
3/3/2025
|
Sell |
Huizenga, Theodore Alan |
SVP, Chief Accounting Officer |
$42.1 |
$40,711 |
|
3/3/2025
|
Sell |
Harris, Erik |
EVP & Chief Commercial Officer |
$42.1 |
$635,836 |
|
3/3/2025
|
Sell |
Kakkis, Emil D. |
President & CEO |
$42.1 |
$3,091,571 |
|
3/3/2025
|
Sell |
Pinion, John Richard |
Officer |
$42.1 |
$607,882 |
|
3/3/2025
|
Sell |
Crombez, Eric |
EVP and Chief Medical Officer |
$42.1 |
$376,585 |
|
3/3/2025
|
Sell |
Parschauer, Karah Herdman |
EVP and Chief Legal Officer |
$42.1 |
$540,817 |
|
3/3/2025
|
Sell |
Kassberg, Thomas Richard |
CBO & EVP |
$42.1 |
$253,779 |
|
2/28/2025
|
Sell |
Kakkis, Emil D. |
President & CEO |
$42.5 |
$1,062,000 |
|
2/27/2025
|
Sell |
Parschauer, Karah Herdman |
EVP and Chief Legal Officer |
$42.8 |
$128,224 |
|
12/30/2024
|
Sell |
Kakkis, Emil D. |
President & CEO |
$42.2 |
$495,231 |
|
12/10/2024
|
Sell |
Kakkis, Emil D. |
President & CEO |
$50.0 |
$413,650 |
|
10/10/2024
|
Sell |
Horn, Howard |
Chief Financial Officer |
$52.8 |
$393,853 |
|
9/3/2024
|
Sell |
Huizenga, Theodore Alan |
SVP, Chief Accounting Officer |
$56.2 |
$5,113 |
|
9/3/2024
|
Sell |
Kakkis, Emil D. |
President & CEO |
$55.8 |
$1,117,000 |
All information without guarantee! No recommendation/consultation! © U.S. Securities and Exchange Commission (SEC)
Free Updates via Email
Please confirm your email address